PROPANC BIOPHARMA, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
PROPANC BIOPHARMA, INC. (PPCB) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $179.31 thousand for the 12-month period ending 2018-06-30, per its 10-K filed 2018-09-17.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2018-09-17
- PROPANC BIOPHARMA, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2018 was $179.31K, a 41.34% decline from fiscal 2017.
- PROPANC BIOPHARMA, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2017 was $305.67K.
- PROPANC BIOPHARMA, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2016 was -$72.54K, a 193.63% decline from fiscal 2015.
- PROPANC BIOPHARMA, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2015 was $77.47K, a 60.50% increase from fiscal 2014.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month as first filed |
|---|---|---|
| 2018-06-30 | $179.31K 10-K · filed 2018-09-17 | |
| 2017-06-30 | $305.67K 10-K · filed 2018-09-17 | -$305.67K 10-K · filed 2017-09-28 |
| 2016-06-30 | -$72.54K 10-K · filed 2017-09-28 | $72.54K 10-K · filed 2016-09-28 |
| 2015-06-30 | $77.47K 10-K · filed 2016-09-28 | |
| 2014-06-30 | $48.27K 10-K · filed 2015-09-30 | |
| 2013-06-30 | $60.46K 10-K · filed 2014-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |